Finally, SOD mimetics that enhance SOD activity have exhibited limited clinical efficacy, as seen in clinical trials that have not shown significant benefits in neurodegenerative diseases, such as Alzheimer’s disease [11]. This evidence concerns the gene SOD1 and early-onset autosomal dominant Alzheimer disease.